Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2022 Filed May 5, 2022 21:52 UTC |
Szyman Catherine M.CVP, Critical Care
|
Tax withholdingCommon Stock | 493 | $105.93 | $52,223.49 |
DisclosureSEC source: 0001225208-22-006584 · doc4.xml · nonDerivative · entry 3 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,250.6569 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:52 UTC |
Szyman Catherine M.CVP, Critical Care
|
Exercise / conversionCommon Stock | 23,400 | $21.76 | $509,184.00 |
DisclosureSEC source: 0001225208-22-006584 · doc4.xml · nonDerivative · entry 2 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,743.6569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC |
SELLERS ROBERT W.A.SVP, Corporate Controller
|
Tax withholdingCommon Stock | 116 | $105.93 | $12,287.88 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,936.4609 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 441 | $105.93 | $46,715.13 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 3 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,883 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
Tax withholdingCommon Stock | 279 | $105.93 | $29,554.47 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,798 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:50 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
Tax withholdingCommon Stock | 42 | $105.93 | $4,449.06 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · nonDerivative · entry 2 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,034.3402 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:50 UTC |
Wood Larry LCVP, TAVR
|
Tax withholdingCommon Stock | 567 | $105.93 | $60,062.31 |
DisclosureSEC source: 0001225208-22-006580 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,499.0338 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:50 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 496 | $105.93 | $52,541.28 |
DisclosureSEC source: 0001225208-22-006578 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,919.7842 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:49 UTC |
STONE HEISZ LESLIEDirector
|
GrantDirector Stock Option (Right to Acquire) · Derivative | 2,209 | $0.00 Strike: $108.65 | $0.00 |
DisclosureSEC source: 0001225208-22-006576 · doc4.xml · derivative · entry 2 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,209 Underlying: Common Stock · 2,209 shares Expires 2029-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and became fully exercisable on the grant date. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:49 UTC |
STONE HEISZ LESLIEDirector
|
GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006576 · doc4.xml · nonDerivative · entry 1 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,480 F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:48 UTC |
Marsh Martha H.Director
|
GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006574 · doc4.xml · nonDerivative · entry 1 Marsh Martha H. · CIK 0001500281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,077 F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 04, 2022 Filed May 10, 2022 20:39 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006786 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,037 F2 · shares: This restricted stock was granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 04, 2022 Filed May 10, 2022 20:39 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006786 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · shares: These restricted stock units were granted on May 4, 2022 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Zovighian Bernard JCVP, TMTT
|
GrantPerformance Rights · Derivative | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006585 · doc4.xml · derivative · entry 4 Zovighian Bernard J · CIK 0001665141 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Zovighian Bernard JCVP, TMTT
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 33,700 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006585 · doc4.xml · derivative · entry 3 Zovighian Bernard J · CIK 0001665141 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 33,700 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Zovighian Bernard JCVP, TMTT
|
GrantCommon Stock | 4,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006585 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · CVP, TMTT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,576 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantPerformance Rights · Derivative | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006584 · doc4.xml · derivative · entry 8 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,725 Underlying: Common Stock · 4,725 shares Expires not disclosed F7 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F7 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 30,600 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006584 · doc4.xml · derivative · entry 7 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Underlying: Common Stock · 30,600 shares Expires 2029-05-02 F6 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:52 UTC |
Szyman Catherine M.CVP, Critical Care
|
GrantCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006584 · doc4.xml · nonDerivative · entry 1 Szyman Catherine M. · CIK 0001438538 · CVP, Critical Care 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,343.6569 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
SELLERS ROBERT W.A.SVP, Corporate Controller
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 3,480 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · derivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,480 Underlying: Common Stock · 3,480 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
SELLERS ROBERT W.A.SVP, Corporate Controller
|
GrantCommon Stock | 1,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,052.4609 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantPerformance Rights · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · derivative · entry 6 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 40,600 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · derivative · entry 5 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,600 Underlying: Common Stock · 40,600 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006582 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,324 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantPerformance Rights · Derivative | 4,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · derivative · entry 4 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,075 Underlying: Common Stock · 4,075 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 26,400 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC |
Chopra DaveenCVP, Surgical Structural Heart
|
GrantCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006581 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, Surgical Structural Heart 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,077 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantPerformance Rights · Derivative | 3,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · derivative · entry 4 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,425 Underlying: Common Stock · 3,425 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 24,500 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · derivative · entry 3 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Lemercier Jean-Luc MCVP, EMEA, Canada, Latin Amer
|
GrantCommon Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006579 · doc4.xml · nonDerivative · entry 1 Lemercier Jean-Luc M · CIK 0001710625 · CVP, EMEA, Canada, Latin Amer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,076.3402 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Wood Larry LCVP, TAVR
|
GrantPerformance Rights · Derivative | 5,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006580 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Wood Larry LCVP, TAVR
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 39,800 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006580 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,800 Underlying: Common Stock · 39,800 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
Wood Larry LCVP, TAVR
|
GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006580 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,066.0338 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006578 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,725 Underlying: Common Stock · 4,725 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 33,900 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006578 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,900 Underlying: Common Stock · 33,900 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantCommon Stock | 3,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006578 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,415.7842 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantPerformance Rights · Derivative | 26,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006577 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,550 Underlying: Common Stock · 26,550 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 190,400 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006577 · doc4.xml · derivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,400 Underlying: Common Stock · 190,400 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:50 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GrantCommon Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006577 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,521.82 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · derivative · entry 10 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,050 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 8 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,394,017 Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,271.82 Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 11,427 | $109.12 | $1,246,914.24 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,771.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F6 · price: This transaction was executed in multiple trades at prices ranging from $108.500 to $109.500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 8,934 | $105.81 | $945,306.54 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,198.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $105.390 to $106.380. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 7,967 | $107.94 | $859,957.98 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,132.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $107.410 to $108.395. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 2,276 | $106.86 | $243,213.36 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,099.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $106.395 to $107.300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
SaleCommon Stock | 1,946 | $109.69 | $213,456.74 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,375.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $109.520 to $109.810. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 23:54 UTC |
MUSSALLEM MICHAEL ADirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-22-006312 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,321.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 01:02 UTC |
Marsh Martha H.Director
|
Exercise / conversionDirector Stock Option (Right to Acquire) · Derivative | 28,722 | $0.00 Strike: $25.99 | $0.00 |
DisclosureSEC source: 0001225208-22-006244 · doc4.xml · derivative · entry 3 Marsh Martha H. · CIK 0001500281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,722 shares Expires 2022-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 01:02 UTC |
Marsh Martha H.Director
|
SaleCommon Stock | 28,722 | $108.09 | $3,104,563.85 |
DisclosureSEC source: 0001225208-22-006244 · doc4.xml · nonDerivative · entry 2 Marsh Martha H. · CIK 0001500281 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,777 F1 · price: This transaction was executed in multiple trades at prices ranging from $108.00 to $108.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.